Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal C...
March 13 2018 - 07:00AM
- NSI-566 shown to have restorative function in
primate paralysis model -
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused
on developing novel treatments for nervous system diseases,
highlighted the publication of a manuscript in Nature Medicine
showing that NSI-566, Neuralstem’s lead cell therapy candidate,
provided meaningful improvement in forelimb function in a non-human
primate model of acute spinal cord injury. The full manuscript can
be found here.
The manuscript, entitled ‘Restorative Effects of Human Neural
Stem Cell Grafts on the Primate Spinal Cord,’ involved a study to
evaluate the potential benefits of transplanting NSI-566 into
rhesus monkeys two weeks after they received a hemisection lesion
of the cervical spinal cord.
Key Findings:
- NSI-566 was observed to extend hundreds of thousands of axons
long distances from the graft site which appear to form synaptic
connections with host neurons, including motor neuron
populations;
- Host corticospinal axons regenerate into the NSI-566
graft;
- Grafting of NSI-566 led to a measurable improvement in forelimb
function in injured animals.
The study was led by researchers at the University of California
San Diego School of Medicine and builds on their previous work
showing that grafted NSI-566 cells promote locomotor recovery in
rats subjected to severe spinal cord injury.
“This study strengthens our conviction that NSI-566
could potentially confer a benefit in patients with motor
deficits from spinal injury and supports our ongoing efforts in
addressing conditions involving paralysis, such as ALS and stroke,"
said Richard Daly, Neuralstem’s Chairman and CEO.
About NSI-566
Neuralstem’s stem cell therapy product candidate, NSI-566, is a
spinal cord-derived neural stem cell line. Neuralstem is currently
evaluating NSI-566 in three indications: ischemic stroke,
Amyotrophic Lateral Sclerosis (ALS), and chronic spinal cord injury
(cSCI).
Neuralstem is conducting a Phase 1 safety study for the
treatment of paralysis from chronic motor stroke at the BaYi Brain
Hospital in Beijing, China. In addition, NSI-566 was
evaluated in a Phase 1 safety study to treat paralysis due to
chronic spinal cord injury as well as Phase 1 and Phase 2a dose
escalation, safety trials for ALS. Subjects from all three
indications are currently in long-term observational follow-up
periods to continue to monitor safety and possible therapeutic
benefits.
About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company
developing novel treatments for nervous system diseases of high
unmet medical need. The Company has two lead development
candidates:
- NSI-189, is a small molecule in clinical development for major
depressive disorder (MDD) and in preclinical development for
Angelman syndrome, irradiation-induced cognitive impairment, Type 1
and Type 2 diabetes, and stroke.
- NSI-566 is a stem cell therapy being tested for treatment of
paralysis in ischemic stroke, Amyotrophic Lateral Sclerosis (ALS)
and chronic spinal cord injury (cSCI).
Neuralstem’s diversified portfolio of product candidates is
based on its proprietary neural stem cell technology.
Cautionary Statement Regarding Forward Looking
Information
This news release contains “forward-looking statements” made
pursuant to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements
relate to future, not past, events and may often be identified by
words such as “expect,” “anticipate,” “intend,” “plan,” “believe,”
“seek” or “will.” Forward-looking statements by their nature
address matters that are, to different degrees, uncertain. Specific
risks and uncertainties that could cause our actual results to
differ materially from those expressed in our forward-looking
statements include risks inherent in the development and
commercialization of potential products, uncertainty of clinical
trial results or regulatory approvals or clearances, need for
future capital, dependence upon collaborators and maintenance of
our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
from time to time in Neuralstem’s periodic reports, including the
Annual Report on Form 10-K for the year ended December 31, 2016,
and Form 10-Q for the three and nine months ended September 30,
2017, filed with the Securities and Exchange Commission (SEC), and
in other reports filed with the SEC. We do not assume any
obligation to update any forward-looking statements.
Contact:
Kimberly MinarovichArgot Partners (Investor
Relations)212-600-1902neuralstem@argotpartners.com
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Mar 2023 to Mar 2024